FCGR2A variant rs1801274 as a Pharmacogenetic Predictor of Natalizumab Therapeutic Failure in Multiple Sclerosis Patients

Vol 1, 2024 - 306901
Poster Presentation
Favorite this paper
How to cite this paper?
Abstract

Background:Multiple sclerosis (MS) is recognized as the most prevalent autoimmune disorder affecting the central nervous system (CNS). Natalizumab (NTZ) is among the commonly used second-line treatments, showing efficacy in decreasing MS activity in most patients. NTZ binds to the α4β1 and α4β7 integrins, inhibiting leukocyte migration through the blood-brain barrier to the CNS. Genetic factors can significantly influence the therapeutic outcomes of MS treatment. However, there are few pharmacogenetic predictors of therapeutic outcomes in the treatment of MS patients. One genetic variant associated with therapeutic response to monoclonal antibodies used in treatment is the single nucleotide polymorphism (SNP) rs1801274 in the FCGR2A gene. Therefore, this study aims to analyze the feasibility of this genetic variant as a potential pharmacogenetic predictor of therapeutic failure in Natalizumab treatment among MS patients. Methods: 104 blood samples were collected from patients admitted to two university hospitals in Rio de Janeiro, with approval from the ethics committee (CAAE: 5,782,087). Genomic DNA was extracted from leukocytes for subsequent genotyping by TaqMan-PCR assay. Results:Among the patients, 9 exhibited confirmed therapeutic failure to NTZ treatment. Following statistical analysis, a significant association was identified between the GG genotype of FCGR2A (p=0.0004, OR=0.3530) and therapeutic failure. Additionally, a higher frequency of the AG genotype was observed in patients who did not experience therapeutic failure (p=0.0002, OR=3.144). Conclusions: Previous research has posited that FCgRs may also impact the efficacy and tolerability of human monoclonal antibody strategies targeting anti-alpha-4 integrin. Given the genetic diversity of the Brazilian population due to miscegenation, our preliminary findings suggest the necessity to investigate the role of FCGR2A rs1801274 as a potential pharmacogenetic predictor for MS patient's response to NTZ.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 University of the state of Rio de Janeiro
  • 2 Rio de Janeiro State University
  • 3 Federal University of the State of Rio de Janeiro
Track
  • Basic and Clinical Neuroscience - Poster
Keywords
Pharmacogenetics
Therapeutic Failure
Multiple Sclerosis
Natalizumab